Celgene Corporation (CELG) Shares are Up 3.9%

Celgene Corporation (CELG) has been under a strong bear grip, hence the stock is down -1.23% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.34% in the past 1 week. The stock has risen by 3.9% in the past week indicating that the buyers are active at lower levels, but the stock is down -3.23% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 0.32% and the 50-Day Moving Average is 0.24%.The 200 Day SMA reached 2.65% Celgene Corporation is up 9.93% in the last 3-month period. Year-to-Date the stock performance stands at -9.37%.


Celgene Corporation (CELG) : 14 investment research analysts covering Celgene Corporation (CELG) have an average price target of $141.79 for the near short term. The highest target price given by the Brokerage Firm to the stock is $162 and the lowest target is $120 for the short term. Analysts expect the variance to be within $12.26 of the average price.

For the current week, the company shares have a recommendation consensus of Buy. Celgene Corporation (NASDAQ:CELG): The stock opened at $107.13 and touched an intraday high of $108.88 on Friday. During the day, the stock corrected to an intraday low of $106.7, however, the bulls stepped in and pushed the price higher to close in the green at $108.54 with a gain of 1.11% for the day. The total traded volume for the day was 5,923,959. The stock had closed at $107.35 in the previous trading session.

Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.